Healthcare data analytics company Health Catalyst (NASDAQ:HCAT) announced better-than-expected revenue in Q3 CY2025, but sales were flat year on year at $76.32 million. On the other hand, next quarter’s revenue guidance of $73.5 million was less impressive, coming in 1.7% below analysts’ estimates. Its non-GAAP profit of $0.06 per share was in line with analysts’ consensus estimates.
Healthcare data analytics company Health Catalyst (NASDAQ:HCAT) will be reporting results this Monday after market hours. Here’s what you need to know.
The Russell 2000 (^RUT) is home to many small-cap stocks, offering investors the chance to uncover hidden gems before the broader market catches on.
However, these companies often come with higher volatility and risk, as their smaller size makes them more vulnerable to economic downturns.
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the data analytics industry, including Health Catalyst (NASDAQ:HCAT) and its peers.
A number of stocks jumped in the afternoon session after a key inflation report came in cooler than anticipated, fueling hopes for a shift in the Federal Reserve's interest rate policy. The latest Consumer Price Index (CPI) report showed a 3.0% year-over-year increase, slightly below the 3.1% that analysts had expected. This moderation in inflation is a significant signal for investors, suggesting that price pressures may be easing. For the tech sector, which is often sensitive to interest rate changes, this news was particularly welcome. Softer inflation could give the Federal Reserve the flexibility to pause or even begin cutting interest rates. Lower rates reduce borrowing costs for growth-oriented tech companies and increase the present value of their future earnings, making their stocks more attractive to investors.
Wall Street has set ambitious price targets for the stocks in this article.
While this suggests attractive upside potential, it’s important to remain skeptical because analysts face institutional pressures that can sometimes lead to overly optimistic forecasts.
A number of stocks jumped in the afternoon session after positive news on corporate earnings, easing political and trade tensions, and optimism about future interest rate cuts all converged to lift investor sentiment.
Rapid spending isn’t always a sign of progress.
Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them vulnerable.
Rock-bottom prices don't always mean rock-bottom businesses.
The stocks we're examining today have all touched their 52-week lows, creating a classic investor's dilemma: bargain opportunity or value trap?
A number of stocks fell in the afternoon session after President Trump threatened to increase import taxes on Chinese goods, reigniting trade war fears.
A number of stocks fell in the afternoon session after markets pulled back as a report raised concerns about artificial intelligence demand and profitability.
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions.
While many thrive during risk-on environments, many also struggle to maintain investor confidence when the ride gets bumpy.
A number of stocks jumped in the afternoon session after investors scooped up equities, shaking off the initial concerns inferred from the Fed's dot plot, with tech stocks leading the charge.
The low valuation multiples for value stocks provide a margin of safety that growth stocks rarely offer.
However, the challenge lies in determining whether these cheap assets are genuinely undervalued or simply on sale due to their potentially deteriorating business models.
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
Investors looking for hidden gems should keep an eye on small-cap stocks because they’re frequently overlooked by Wall Street.
Many opportunities exist in this part of the market, but it is also a high-risk, high-reward environment due to the lack of reliable analyst price targets.
Shares of healthcare data analytics company Health Catalyst (NASDAQ:HCAT) fell 4.1% in the morning session after Piper Sandler downgraded the stock's rating to Neutral from Overweight and slashed its price target in half.
